Compare Novavax Inc (NVAX) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Novavax Inc trades at $12.64 (market cap $1.82B), while GraniteShares 2x Long NVDA Daily ETF trades at $36.94 (market cap $3.56B). The key difference: GraniteShares 2x Long NVDA Daily ETF is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and GraniteShares 2x Long NVDA Daily ETF for 15 Days on average.
| NVAX | NVDL | |
|---|---|---|
Market Cap | $1.82B | $3.56B |
Volume | 6,198,505 | 9,740,643 |
Sector | Health | Leveraged / Inverse |
52-Week High | $12.56 | $43.02 |
52-Week Low | $6.22 | $21.76 |
Typical Hold Time | 59 Days | 15 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $37.335, down 5.65% on the day. Technical indicators show a bullish overall signal with strong moving average support, though oscillators remain neutral. Recent news highlights Nvidia's continued AI leadership and earnings beats, driving leveraged ETF interest. The ETF aims to deliver 2x daily returns of Nvidia stock, with technical analysis showing support at $36 and resistance at $38-39 levels.
The outlook remains tied to Nvidia's AI dominance and earnings performance. Investment opportunity exists through leveraged exposure to Nvidia's growth trajectory, though risks include daily reset leverage decay and Nvidia's high valuation. Recent SpaceX earnings have reshuffled AI chip trades, creating volatility. The ETF's performance depends on Nvidia maintaining its AI market leadership and execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
